Among 572 people with liver cancer in hospitals and oncology centres in Bishkek, Osh and Jalal-Abad, hepatitis B accounted for 32% and hepatitis C for 32%. Half of the liver cancer patients tested for hepatitis D antibodies were positive.
Published as "Liver cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C in Kyrgyzstan, 2019-2024: a prospective and retrospective study", led by the Robert Koch Institute in Berlin with Kyrgyz co-authors and funded by Germany's Global Health Protection Programme. The authors collected information on patients with cirrhosis or hepatocellular carcinoma from medical records in clinical hospitals and oncology centres in Bishkek, Osh and Jalal-Abad, prospectively from August 2023 to April 2024 and retrospectively from January 2019 to July 2023.
About six in ten of the liver cancers studied (348 of 572, counting the 17 people with both infections once) were attributed to hepatitis B or C, infections that can be prevented by vaccination or treated. The authors call for earlier testing and treatment. Liver cancer is the third commonest cause of cancer death in IARC's 2024 estimate for Kyrgyzstan.
Shares Osh Interregional Oncology Centre, Ministry of Health of the Kyrgyz Republic, National Center of Oncology and Hematology of the Kyrgyz Republic.
Shares Ministry of Health of the Kyrgyz Republic, National Center of Oncology and Hematology of the Kyrgyz Republic.
Shares Osh Interregional Oncology Centre, Ministry of Health of the Kyrgyz Republic.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/